Brief: Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager Platform Candidates
07/11/2022 14:02
Nov 7 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS PRESENTS UPDATED PRECLINICAL DATA ON GAMMA
DELTA T
CELL ENGAGER (GADLEN) PLATFORM CANDIDATES AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING
* SHATTUCK LABS INC - DATA FROM TWO DISTINCT GADLEN PRODUCT
CANDIDATES DEMONSTRATES PRECLINICAL PROOF-OF-CONCEPT IN
TREATMENT OF CANCER
Source text for Eikon: ID:nGNX14M3Td
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health